Nearly one-third of clinical trial sites expect the novel coronavirus will have a “big or extremely big” impact on their ability to recruit patients for new trials or keep patients already enrolled in existing studies compliant with scheduling, a new survey finds.

In addition, 39% of 170 clinical trial sites surveyed in the U.S. believe patients will be much less or somewhat less likely to enroll in new clinical research trials. And 25% of the sites expect patients currently enrolled in a trial to be much less or somewhat less willing to continue their participation.